Express Computer
Home  »  News  »  Aurigene Pharmaceutical Services Ltd. introduces Aurigene.AI, an AI and ML assisted drug discovery platform

Aurigene Pharmaceutical Services Ltd. introduces Aurigene.AI, an AI and ML assisted drug discovery platform

0 42

Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organisation and a Dr. Reddy’s Laboratories company, introduces Aurigene.AI, an AI and ML-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination. Aurigene.AI combines advanced physics-based simulation, generative and predictive AI models, and CADD (Computer-Aided Drug Design) in one platform, allowing users to pick the appropriate algorithms for a given application. The modular platform also consists of a meticulously curated database of 180 million compounds and 1.6 million validated bioassay data points. This database is ever-expanding and serves as training data for the platform.

Aurigene.AI is hosted on Google Cloud, which offers a scalable infrastructure for handling large datasets
and efficient computation while safeguarding client data confidentiality. Integrating AI and ML-based solutions with Aurigene's core capabilities in chemical design, synthesis, and assessment in bioassays will facilitate faster development of novel therapeutics. Discovery scientists at Aurigene have validated the platform using a case study and demonstrated that the application of Aurigene.AI reduced the cycle time from chemical design to synthesis and testing by 35%.

Akhil Ravi, CEO, Aurigene Pharmaceutical Services Ltd., said, We are committed to continually advancing our service experience and providing innovative end-to-end solutions to our global partners. Aurigene.AI is an important addition to our small molecule discovery offering and represents a data-driven approach to novel therapeutic development. Dr. Gayathri Ramaswamy, Global Head of Discovery Services, Aurigene Pharmaceutical Services Ltd., said, The addition of AI and iterative machine learning capabilities to our core expertise in synthesizing and testing molecules will significantly reduce the DMTA cycle time in the discovery process. Aurigene.AI augments our core scientific capabilities in the small molecule discovery space and will serve as an efficient engine for identifying a drug candidate.

Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.

LIVE Webinar

Digitize your HR practice with extensions to success factors

Join us for a virtual meeting on how organizations can use these extensions to not just provide a better experience to its’ employees, but also to significantly improve the efficiency of the HR processes
REGISTER NOW 
India's Leading e-Governance Summit is here!!! Attend and Know more.
Register Now!
close-image
Attend Webinar & Enhance Your Organisation's Digital Experience.
Register Now
close-image
Enable A Truly Seamless & Secure Workplace.
Register Now
close-image
Attend Inida's Largest BFSI Technology Conclave!
Register Now
close-image
Know how to protect your company in digital era.
Register Now
close-image
Protect Your Critical Assets From Well-Organized Hackers
Register Now
close-image
Find Solutions to Maintain Productivity
Register Now
close-image
Live Webinar : Improve customer experience with Voice Bots
Register Now
close-image
Live Event: Technology Day- Kerala, E- Governance Champions Awards
Register Now
close-image
Virtual Conference : Learn to Automate complex Business Processes
Register Now
close-image